Rocket Pharmaceuticals adjusted the clinical trial design to include use of approved drug to avert an excessive immune response to its Danon disease gene therapy. The patient who died was one of two who received this drug under the revised protocol. The post Death in Rocket Pharma Gene Therapy Study Puts Spotlight on Trial Change…
The status quo for medical malpractice insurance is no longer good enough. While we must always prioritize the need for accountability when it comes to medical malpractice, we must also consider how challenges like increased premiums, rising costs and new risks are impacting providers and consequentially patients. The post It’s Time for Medical Malpractice Insurance…
Experts believe value-based care won’t ever reach scale unless fundamental barriers are addressed — including voluntary models, misaligned payer incentives, excessive metrics and weak employer engagement. The post What’s Standing in the Way of Healthcare Payment Reform? appeared first on MedCity News.
We can’t ignore what AI makes possible: faster diagnoses, smarter workflows, better use of limited resources, and more personalized care at scale. If we get this right, we can build a system that works better for everyone, not just the few who can afford concierge care or live near major medical centers. The post AI…
This Health System Tracker analysis examines the tradeoffs ACA Marketplace enrollees must consider as they decide whether to keep their current plan or switch to a new one, following the expiration of the ACA’s enhanced premium tax credits at the end of 2025.
Herself Health and Blue Cross and Blue Shield of Minnesota have shifted away from a fee-for-service arrangement to a value-based arrangement. The post Blue Cross and Blue Shield of Minnesota, Herself Health Shift To VBC Contract appeared first on MedCity News.
By aligning innovative scientific insights with strategic commercial pathways, the industry has the potential to fulfill its early promise – delivering safe, effective therapies that improve patient outcomes and create new opportunities for growth in the biopharmaceutical sector. The post Beyond the Hype: The Scientific and Commercial Future of Microbiome Medicine appeared first on MedCity…
Many healthcare experts are calling Omada Health and Hinge Health’s IPO debuts a success, though it’s still early days. The post Omada & Hinge’s IPO Debuts Signal Success for Digital Health Market, Experts Say appeared first on MedCity News.
Ulcerative colitis is the lead indication for Odyssey Therapeutics’ internally discovered lead drug candidate. With the IPO proceeds, Odyssey plans mid-stage clinical trials evaluating the small molecule in combination with Takeda’s Entyvio and as a monotherapy. The post Odyssey’s IPO Brings In $304M for Quest to Develop Better Immunology Drugs appeared first on MedCity News.
KFF Health News senior contributing editor Elisabeth Rosenthal discussed the cost of cancer care in the wake of James Van Der Beek’s death on ABC News’ ABC News Live on Feb. 12. Click here to watch Rosenthal on ABC News Live. KFF Health News Southern California correspondent Claudia Boyd-Barrett discussed how families of detainees by the U.S….